Formulations:
- Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule
Oral > Solid: 400 mg; 600 mg
Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 2 mL ampoule
Oral > Solid > tablet: 400 mg; 600 mg
Oral > Other: 600 mg
Oral > Solid > tablet: 400 mg
Indications:
- Unspecified malignant neoplasms of ill-defined or unspecified sites
- Osteosarcoma of bone and articular cartilage of other specified sites
- Burkitt lymphoma including Burkitt leukaemia
- Ewing sarcoma of bone and articular cartilage of unspecified sites
- Malignant neoplasms of kidney, except renal pelvis
- Other specified malignant neoplasms of the ovary
- Germ cell tumour of testis
- Rhabdomyosarcoma primary site
Source: EML workbook import
Product metadata will be available once the catalog entry is complete.
Formulations:
- Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule
Oral > Solid: 400 mg; 600 mg
Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 2 mL ampoule
Oral > Solid > tablet: 400 mg; 600 mg
Oral > Other: 600 mg
Oral > Solid > tablet: 400 mg
Indications:
- Unspecified malignant neoplasms of ill-defined or unspecified sites
- Osteosarcoma of bone and articular cartilage of other specified sites
- Burkitt lymphoma including Burkitt leukaemia
- Ewing sarcoma of bone and articular cartilage of unspecified sites
- Malignant neoplasms of kidney, except renal pelvis
- Other specified malignant neoplasms of the ovary
- Germ cell tumour of testis
- Rhabdomyosarcoma primary site
Source: EML workbook import